Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2020 11:18 ET | Source: Alimera Sciences, Inc.

UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
September 09, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
September 08, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland

ATLANTA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
September 01, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
August 26, 2020 08:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the Netherlands

ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
August 25, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the LD Micro 500 Virtual Conference on September 2, 2020

ATLANTA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
August 13, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries

ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
July 29, 2020 16:05 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Second Quarter and Recent Company Highlights: Consolidated Net Revenue Down 8% Compared to Second Quarter 2019International Net Revenue Up 89% Compared to Second Quarter 2019Net Loss of $2.5...
July 22, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update

ATLANTA, July 22, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
July 09, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Initiates Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

A randomized, controlled, multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care ...